Relationship of tacrolimus exposure and mycophenolate mofetil dose with renal function after renal transplantation

Transplantation

Volumn 92, Issue 1, 2011, Pages 82-87

  Ekberg, Henrik ^a   Van Gelder, Teun ^b   Kaplan, Bruce ^c   Bernasconi, Corrado ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF ARIZONA COLLEGE OF MEDICINE   (United States)

^d F HOFFMANN LA ROCHE LTD   (Switzerland)

Author keywords

Calcineurin inhibitor; Glomerular filtration rate; Nephrotoxicity

Indexed keywords

CORTICOSTEROID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; AGE; ARTICLE; CHRONIC KIDNEY DISEASE; DELAYED GRAFT FUNCTION; DOSE RESPONSE; DRUG EXPOSURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DONOR; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; PRIORITY JOURNAL; RISK FACTOR;

ADULT; CALCINEURIN; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LINEAR MODELS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYCOPHENOLIC ACID; TACROLIMUS;

EID: 79959661813     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e31821fad06     Document Type: Article

References (20)

1. Meier-Kriesche UH, Li S, Gruessner RW, et al. Immunosuppression: Evolution in practice and trends, 1994-2004. Am J Transplant 2006; 6(5 pt 2): 1111.
2. 2007 OPTN/SRTR Annual Report. Available at: http://www.ustransplant. org/annual-reports/current/109a-DH.htm. Accessed November 2, 2010.
3. Padiyar A, Augustine JJ, Hricik E. Induction antibody therapy in kidney transplantation. Am J Kidney Dis 2009; 54: 935.
4. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
5. Gaston RS, Kaplan B, Shah T, et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: The Opticept Trial. Am J Transplant 2009; 9: 1607.
6. Prograf US prescribing information, 2009. Available at: http://www. astellas.us/docs/prograf.pdf or http://www.accessdata.fda.gov/Scripts/ cder/DrugsatFDA/. Accessed November 2, 2010.
7. Nankivell BJ, Borrows RJ, Fung CL, et al. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326.
8. Frei U, Daloze P, Vitko S, et al. Acute rejection in low-toxicity regimens: Clinical impact and risk factors in the Symphony study. Clin Transplant 2010; 24: 500.
9. Klein IH, Abrahams A, van ET, et al. Different effects of tacrolimus and cyclosporine on renal hemodynamics and blood pressure in healthy subjects. Transplantation 2002; 73: 732.
10. Nankivell BJ, Chapman JR, Bonovas G, et al. Oral cyclosporine but not tacrolimus reduces renal transplant blood flow. Transplantation 2004; 77: 1457.
11. Jain S, Bicknell GR, Nicholson ML. Tacrolimus has less fibrogenic potential than cyclosporin A in a model of renal ischaemia-reperfusion injury. Br J Surg 2000; 87: 1563.
12. Naesens M, Kuypers DR, Sarwal M. Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 2009; 4: 481.
13. van Gelder T, Silva HT, de Fijter JW, et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: The fixed-dose concentration-controlled trial. Transplantation 2008; 86: 1043.
14. Vincenti F, Ramos E, Brattstrom C, et al. Multicenter trial exploring calcineurin inhibitors avoidance in renal transplantation. Transplantation 2001; 71: 1282.
15. Wissing KM, Fomegné G, Broeders N, et al. HLA mismatches remain risk factors for acute kidney allograft rejection in patients receiving quadruple immunosuppression with anti-interleukin-2 receptor antibodies. Transplantation 2008; 85: 411.
16. Gentil MA, Osuna A, Capdevilla L, et al. Daclizumab combined with mycophenolate mofetil and late onset of low dose tacrolimus as a therapeutic option for elderly donor-recipient pairs in kidney transplant. Nefrología 2008; 28: 287.
17. Badowski M, Gurk-Turner C, Cangro C, et al. The impact of reduced immunosuppression on graft outcomes in elderly renal transplant recipients. Clin Transplant 2009; 23: 930.
18. Hoshinaga K, Aikawa A, Murai M, et al. Regimen of tacrolimus-based immunosuppression with basiliximab, mycophenolate mofetil, and low-dose steroid reduces acute rejection in kidney transplants. Transplant Proc 2005; 37: 1762.
19. Cosio FG, Am H, Grande JP, et al. Comparison of low versus high tacrolimus levels in kidney transplantation: Assessment of efficacy by protocol biopsies. Transplantation 2007; 83: 411.
20. Fangmann J, Arns W, Marti HP, et al. Impact of daclizumab, lowdose cyclosporine, mycophenolate mofetil and steroids on renal function after kidney transplantation. Nephrol Dial Transplant 2009; 25: 283.